A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide. (15th April 2020)

• Record Type: Journal Article
• Authors: Wassner, Chanie; Bradley, Nicole; Lee, Yuman
• Is Part Of: Journal of the International Association of Providers of AIDS Care. Volume 19(2020)
• Publication Date: 2020-04-15
• Subjects: HIV -- tenofovir -- hepatitis B -- postexposure prophylaxis -- pre-exposure prophylaxis; AIDS (Disease) -- Periodicals; 616.9792
• DOI: 10.1177/2325958220919231
• Languages: English
• ISSNs: 2325-9574

Abstract

HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to control viral replication and prevent complications. Some of the older agents are notorious for many side effects, making patient compliance difficult, which is critical to preventing HIV resistance. Tenofovir is one of the newer, more tolerable, nucleotide reverse transcriptase inhibitors on the market; is a mainstay of many antiretroviral therapy combinations; and is now available in 2 different formulations, tenofovir disoproxil fumarate (TDF) and, the more recent, tenofovir alafenamide (TAF). These 2 formulations have very different pharmacokinetics, which seem to affect their efficacy and safety. This manuscript provides insight into the history of TDF and TAF development, their unique pharmacokinetics and pharmacology, clinically important adverse effects, monitoring, interactions, resistance, review of clinical studies, and guideline recommendations and clinical applications for tenofovir's various indications.